Abstract
Background and purposePostoperative radiotherapy (PORT) can potentially lead to radiation pneumonitis. We aim to develop a nomogram predicting the severe acute radiation pneumonitis (SARP, grade ≥3) in patients with non-small cell lung cancer (NSCLC) receiving PORT. Materials and methodsClinical and dose–volume histogram (DVH) factors were collected from 109 patients between 2006 and 2017. The endpoint was the development of SARP within 3 months after PORT. Logistic regression was used to evaluate the prognostic value of each factor in predicting SARP. Nomogram was generated based on multivariate regression coefficients. Area under the ROC curve (AUC), calibration curves, and decision curve analyses (DCA) were conducted to validate the model. ResultsUnivariate and multivariate analysis indicated that total lung mean dose (tlMD) (OR: 1.003, 95%CI: 1.001–1.006, p = 0.013), percentage of ipsilateral lung volume receiving ≥5 Gy (ilV5) (OR: 1.084, 95%CI: 1.020–1.151, p = 0.009), and concurrent chemoradiotherapy (CCRT) (OR: 4.091, 95%CI: 1.331–12.572, p = 0.014) were independent prognosticators of SARP and were included in the nomogram. ROC curves revealed the AUC of the nomogram was 0.842, which was much higher than any factor alone (tlMD: 0.769; ilV5: 0.744; CCRT: 0.661). Calibration curves showed favorable consistency between the predicted SARP and the actual observation. DCA showed satisfactory positive net benefits of the model among most of the threshold probabilities, indicating great clinical effect. ConclusionWe identified that the tlMD (>10.8 Gy), ilV5 (>64.9%), and CCRT could predict SARP among patients with NSCLC receiving PORT. Combining clinical and DVH parameters, a nomogram was first built and validated, showing its potential value in practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.